0
0

Cancer Drug Parity Act of 2021

12/30/2022, 7:48 AM

Congressional Summary of S 3080

Cancer Drug Parity Act of 2021

This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Current Status of Bill S 3080

Bill S 3080 is currently in the status of Bill Introduced since October 27, 2021. Bill S 3080 was introduced during Congress 117 and was introduced to the Senate on October 27, 2021.  Bill S 3080's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of October 27, 2021

Bipartisan Support of Bill S 3080

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
21
Democrat Cosponsors
11
Republican Cosponsors
9
Unaffiliated Cosponsors
1

Policy Area and Potential Impact of Bill S 3080

Primary Policy Focus

Health

Alternate Title(s) of Bill S 3080

Cancer Drug Parity Act of 2021
Cancer Drug Parity Act of 2021
A bill to amend the Employee Retirement Income Security Act of 1974 to require a group health plan (or health insurance coverage offered in connection with such a plan) to provide for cost-sharing for oral anticancer drugs on terms no less favorable than the cost-sharing provided for anticancer medications administered by a health care provider.

Comments